1
|
Duman N, ALzaidi Z, Aynekin B, Taskin D, Demirors B, Yildirim A, Sahin IO, Bilgili F, Turanli ET, Beccari T, Bertelli M, Dundar M. COVID-19 vaccine candidates and vaccine development platforms available worldwide. J Pharm Anal 2021; 11:675-682. [PMID: 34540318 PMCID: PMC8437828 DOI: 10.1016/j.jpha.2021.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Revised: 09/08/2021] [Accepted: 09/13/2021] [Indexed: 12/12/2022] Open
Abstract
The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. The ongoing vaccine studies all over the world against the COVID-19 epidemic have been reviewed. The effects of different vaccine platforms and new variants on vaccine studies were discussed. The effect of vaccines on existing and novel variants was evaluated.
Collapse
Affiliation(s)
- Nilgun Duman
- Department of Medical Genetics, Dragos Hospital Istanbul, Bezmialem Vakif University, Istanbul, 34854, Turkey
| | - Zahraa ALzaidi
- Department of Biotechnology, Faculty of Applied Science, Cukurova University, Adana, 01380, Turkey
| | - Busra Aynekin
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
| | - Duygu Taskin
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
| | - Busra Demirors
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
| | - Abdulbaki Yildirim
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
| | - Izem Olcay Sahin
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
| | - Faik Bilgili
- Department of Economics, Faculty of Economics and Administrative Sciences, Erciyes University, Kayseri, 38030, Turkey
| | - Eda Tahir Turanli
- Department of Molecular Biology and Genetics, Faculty of Science, Acibadem University, 34684, Istanbul, Turkey
| | - Tommaso Beccari
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, 06123, Italy
| | | | - Munis Dundar
- Department of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey
- Corresponding author.
| |
Collapse
|